期刊文献+

罗格列酮对DM2患者血清MMP-9和TIMP-1影响的研究 被引量:2

The Effects of Rosiglitazone on the Serum MMP-9 and TIMP-1 in Type 2 Diabetic
下载PDF
导出
摘要 目的:探讨2型糖尿病(DM2)患者血清基质金属蛋白酶-9(MMP-9)和组织抑制因子1(TIMP-1)的变化,以及罗格列酮治疗对其的影响。方法:临床观察采用随机对照方法,选择100例初诊DM2患者和50例正常人对照。将100例DM2患者分为A组和B组,A组常规降糖治疗,B组在常规治疗基础上加服罗格列酮,16周后测定患者治疗前后血清MMP-9及TIMP-1水平。结果:DM2患者血清MMP-9、TIMP-1及MMP-9/TIMP-1水平较正常对照组显著升高(P<0.01);B组治疗前后血清MMP-9、TIMP-1及MMP-9/TIMP-1显著降低(P<0.01),A组治疗前后血清MMP-9、TIMP-1及MMP-9/TIMP-1差异无统计学意义(P>0.05);且MMP-9与TIMP-1之间,MMP-9/TIMP-1与MMP-9、TIMP-1之间均呈正相关。结论:血清MMP-9与TIMP-1可能与DM2发生、发展有关,罗格列酮能显著降低DM2患者MMP-9与TIMP-1水平,纠正MMP-9/TIMP-1比值,以期达到早期诊治,防止DM2大血管病变的目的。 Objective To explore the change of rosiglitazone on type 2 diabetic patients and the impact on the expressions of MMP-9 and TIMP-1.Methods The clinica1 observation using randomized controlled method,100 patients with DM2 were selected in our study,and 50 healthy adults served as normal control.100 cases of type 2 diabetics were divided into A and B group.The group A was treated only with conventional therapy.The group B was given rosiglitazone besides conventional therapy.And the concentrations of MMP-9 and TIMP-1 in serum were detected before and after therapy.Results The DM2 diabetics group serum MMP-9,TIMP-1 and MMP-9/TIMP-1 levels were obvious higher than the healthy control group(P0.01);The serum levels of MMP-9,TIMP-1,MMP-9/TIMP-1 on B group after treatment were apparently lower than those before treatment and A group after treatment(P0.01),while the serum levels of MMP-9,TIMP-1,MMP-9/TIMP-1 on B group after treatment were no significantly difference(P0.05).There was a positive correlation between MMP-9/TIMP-1 and expression level of MMP-9 and TIMP-1 in DM2 diabetics(r=0.631,r=0.558,all P0.01),the serum level of MMP-9 was also positive correlation with TIMP-1(r=0.717,P0.01).Conclusion There may be a relevance between serum MMP-9,TIMP-1 and the incidence of DM2.Rosiglitazone can significantly reduce the levels of MMP-9 and TIMP-1 in DM2 diabetics,and corrective MMP-9/TIMP-1 ratio,in order to achieve the purpose of early diagnosis and early prevention of DM2 macroangiopathy.
出处 《放射免疫学杂志》 CAS 2012年第6期649-651,共3页 Journal of Radioimmanology
关键词 2型糖尿病 基质金属蛋白酶-9 组织抑制因子-1 罗格列酮 type 2 diabetics MMP-9 TIMP-1 rosiglitazone
  • 相关文献

参考文献9

二级参考文献51

  • 1李晓玲,葛秀兰,朱旅云,胡立叶,王广宇.2型糖尿病大血管病变患者血清基质金属蛋白酶9及其抑制物1的测定[J].实用医学杂志,2005,21(9):896-897. 被引量:3
  • 2周一军,张锦,李莉,彭扬.糖尿病患者动脉粥样硬化斑块内基质金属蛋白酶2和9与斑块稳定的关系[J].中国动脉硬化杂志,2005,13(1):69-72. 被引量:10
  • 3Rovers MM,Schilder AG,Zielhuis GA,Rosenfeld RM,张江平,杨妙丽,张全安.中耳炎[J].国外医学(耳鼻咽喉科学分册),2005,29(3):141-143. 被引量:433
  • 4付绪栋,安琨,王旭光,荣海钦.血清MMP-9与2型糖尿病血管并发症的相关性研究[J].山东医药,2005,45(19):47-48. 被引量:2
  • 5GRUNDY S M, BENJAMIN I J, BURKE G L, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association[J]. Circulation, 1999, 100(10): 1134-1146.
  • 6DEATH A K, FISHER E J, MCGRATH K C, et al. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes [J]. Atherosclerosis, 2003, 168(2): 263-269.
  • 7MORISHIGE K, SHIMOKAWA H, MATSUMOTO Y, et al. Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine eoronary arteries in vivo[J]. Cardiovase Res, 2003, 57(2): 572-585.
  • 8PASTERKAMP G, SCHONEVELD A H, HIJNEN D J, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery[J]. Atherosclerosis, 2000, 150(2): 245-253.
  • 9WOESSNER J F JR. That impish TIMP: the tissue inhibitor of metalloproteinases-3 [J]. J Clin Invest, 2001, 108 (6) : 799 -800.
  • 10BEAUDEUX J L, GIRAL P, BRUCKERT E, et al. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives[J]. Clin Chem Lab Med, 2004, 42 (2) : 121-131.

共引文献14

同被引文献14

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部